{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:23:04Z","timestamp":1788481384036,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:39:05Z","timestamp":1753857545000},"page":"e1065-e1076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2305-3721","authenticated-orcid":false,"given":"Nouman","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6298-0429","authenticated-orcid":false,"given":"Waseem","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-2851","authenticated-orcid":false,"given":"Hafiz Muhammad","family":"Umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3485-5592","authenticated-orcid":false,"given":"Faiza","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-9366","authenticated-orcid":false,"given":"Adeena","family":"Musheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9914-3934","authenticated-orcid":false,"given":"Sukhrob","family":"Makhkamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Nahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-1506","authenticated-orcid":false,"given":"Roha Saeed","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.07.016_bib0001","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.07.016_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.seminhematol.2010.02.006","article-title":"Thrombocytopenia in patients with myelodysplastic syndromes","volume":"47","author":"Bryan","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2025.07.016_bib0003","doi-asserted-by":"crossref","DOI":"10.21037\/aob-20-90","article-title":"Incidence and severity of adverse effects related to platelet transfusion: a narrative review of the literature and the recent hemovigilance data of Japan","volume":"6","author":"Sato","year":"2021","journal-title":"Annals of Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.07.016_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1538-7836.2009.03440.x","article-title":"Development of thrombopoietin receptor agonists for clinical use","volume":"7","author":"Ikeda","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"25","key":"10.1016\/j.clml.2025.07.016_bib0018","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopagfor first-line treatment of intermediate\u2011 or high\u2011risk myelodysplastic syndromes with thrombocytopenia: results of the SUPPORT phase III trial","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2025.07.016_bib0005","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.22.02699","article-title":"eltrombopagfor low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.07.016_bib0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000531146","article-title":"Long-term safety and efficacy of eltrombopagfor Advanced myelodysplastic syndromes or acute myeloid leukemia and severe thrombocytopenia: results of the ASPIRE Extension Study","volume":"146","author":"Mittelman","year":"2023","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.016_bib0020","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"eltrombopagfor advanced myelodysplastic syndromes or acute myeloid leukemia with grade 4 thrombocytopenia: ASPIRE phase II trial","volume":"5","author":"Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.07.016_bib0007","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.07.016_bib0008","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.07.016_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.clml.2025.07.016_bib0009","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long\u2011term follow\u2011up (up to 5 years) of romiplostim vs placebo in lower\u2011risk MDS patients: risk of leukemic progression","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.016_bib0010","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00277-022-04950-4","article-title":"Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis","volume":"101","author":"Wang","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.07.016_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-8722-5-71","article-title":"romiplostim plus lenalidomide versus placebo plus lenalidomide in MDS: a randomized, double\u2011blind phase II study","volume":"5","author":"Wang","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.07.016_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428194.2012.713477","article-title":"A randomized, placebo\u2011controlled trial of romiplostim plus decitabine in patients with low\u2011 or intermediate\u2011risk MDS","volume":"54","author":"Greenberg","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2025.07.016_bib0011","article-title":"Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours","volume":"11","author":"Zhang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.clml.2025.07.016_bib0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.07.016_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.016_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminhematol.2014.10.005","article-title":"Treatment of myelodysplastic syndrome with thrombomimetic drugs","volume":"52","author":"Santini","year":"2015","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.016_bib0015","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.07.016_bib0016","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.clinthera.2020.02.020","article-title":"The cost-effectiveness of eltrombopagfor the treatment of Immune thrombocytopenia in the United States","volume":"42","author":"Tremblay","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2025.07.016_bib0017","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/PPA.S192481","article-title":"Despotovic JM. romiplostim for the treatment of Immune thrombocytopenia: spotlight on patient acceptability and ease of use","volume":"14","author":"Gilbert","year":"2020","journal-title":"Patient prefer adherence"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:11:32Z","timestamp":1763773892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002605"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Thrombopoietin Receptor Agonists on Platelet Transfusion Requirements in Myelodysplastic Syndromes: An Updated Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}